Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Not Applicable
Completed
- Conditions
- Human Papilloma Virus (HPV)
- Interventions
- Device: cobas® 4800 HPV Test
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47208
- Registration Number
- NCT00709891
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00701558
A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT00699348
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 820
- Registration Number
- NCT00700102
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: bevacizumab [Avastin]Drug: Carboplatin-based chemotherapy
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 303
- Registration Number
- NCT00700180
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT00700570
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: ribavirin [Copegus]
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 262
- Registration Number
- NCT00700401
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 292
- Registration Number
- NCT00697203
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
Phase 3
Completed
- Conditions
- Pemphigus Vulgaris (PV)
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00683930
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis
Phase 3
Completed
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Drug: mycophenolate mofetil (CellCept)Drug: placebo
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2008-05-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT00683969
© Copyright 2025. All Rights Reserved by MedPath